Login to Your Account



Off-Label Use a More Attractive Tack?

Roche Won't Move Avastin To FDA in Ovarian Cancer

By Marie Powers
Staff Writer

Tuesday, January 3, 2012
One week after the European Commission approved the use of Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer, findings from two Phase III studies published in the New England Journal of Medicine suggested the drug offered a modest but noticeable benefit over standard chemotherapy in terms of progression-free survival (PFS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription